Yasam Bankasi Famicord

FamiCord Group (operating under the name FamiCord AG since 2025, following the merger of PBKM and Vita 34 in 2021) is the European market leader and the third-largest stem cell bank worldwide. The Group has secured over 1.5 million biological material samples (mostly cord blood, cord tissue, placental blood, placenta). FamiCord has a robust operational infrastructure: 13 processing and storage laboratories, 2 storage only laboratories, and 3 cell & gene GMP centers for CDMO activity, controlling approximately 55-60% of the European cord blood banking market.

Supplying stem cells for medical use remains at the core of the Group's focus. FamiCord actively supports the use of stem cells in treatments, with a history of over 8,500 patients treated with 16,500 stem cell preparations including 278 cord blood applications (as of June 2026). The Group has been involved in several clinical trials in the area of: cardiology, neurology, dermatology, orthopedics and others in the role of sole sponsor, co-sponsor or supplier of cell-based ATMP. FamiCord also actively participates in cerebral palsy treatment programs for children [Expanded Access Program conducted in Lublin, Poland].

The CDMO (Contract Development and Manufacturing Organization) activity, primarily under the Bramble Bio brand, remains an advanced technological pillar. Through 3 specialized CDMO centers located in Germany, Poland and Portugal, the Group provides comprehensive manufacturing services for Advanced Therapy Medicinal Products (ATMPs) in compliance with cGMP standards, strengthening its position as a trusted contract manufacturer for the biotechnology industry.

Regarding the development of CAR-T cell therapies (oncology), the Group has revised its strategy. FamiCordTx, initially developed as an internal venture, is now an independent entity with which FamiCord Group is affiliated (holding an approximately 20% stake). This allows the Group to focus its resources on its core business and commercial B2B services.

The scale of medical operations is built on solid financial foundations. In 2025, FamiCord Group generated sales revenues of EUR 88.17 million (a 7.3% year-over-year increase) with significant proportion of recurrent revenue. The Group achieved an EBITDA of EUR 10.6 million (a 12.3% y/y increase). FamiCord AG is listed at Deutsche Boerse in Franfurt and is backed mostly by financial shareholders (AOC – private equity, SVF – investment fund, Nationale Netherlanden – pension fund and others). This guarantees absolute stability and security for the long-term storage of materials entrusted by patients.

Collection Kit

Supplies are provided for gravity collection into a blood bag.

Transportation container

The container is validated to maintain room temperature under test conditions.

Shipping Info

Shipping is included in the base price within the home country, costs extra from outside.

Processing Method

Cord blood is manually processed.

Components Stored

Parents are provided with a certificate describing test results (cell counts, viability).

Storage Method

Final storage is performed in storage bags, which are enclosed in a storage cassette. First there is temporary storage in the quarantine freezer, then sample are moved to long term freezer. Freezer uses vapor phase of cryogenic nitrogen

Licensing & Accreditation

Licensed by National Ministry of Health Türkiye.

Clinical Experience

FamiCord Group has provided more than 8,500 clinical stem cell therapies worldwide, including both standard hematopoietic stem cell transplantations and experimental/regenerative medicine therapies.
Famicord Group has released 278 cord blood units for therapy as of June 2026.
The Group has extensive experience in releasing autologous cord blood units for children diagnosed with neurological disorders, particularly autism spectrum disorder (ASD) and cerebral palsy (CP), under dedicated therapeutic access programs.
Selected laboratories within the FamiCord network also participate in public cord blood banking programs and collect cord blood donations intended for unrelated donor transplantations.
FamiCord Group actively participates in clinical trials, observational studies, and compassionate use programs involving cord blood and mesenchymal stem cell therapies in neurological, hematological, immunological, and regenerative medicine indications. More information: https://famicord.com/science-and-clinical-trials/
Through its GMP-certified manufacturing facilities in Poland and Portugal, FamiCord develops and manufactures advanced therapy medicinal products (ATMPs) based on cord blood, perinatal tissues, and mesenchymal stem cells. The Group is involved in translational medicine projects focused on developing innovative regenerative therapies and cell-based medicinal products.
FamiCord collaborates with leading hospitals, transplantation centers, and regenerative medicine clinics across Europe and internationally, supporting innovative therapeutic programs using cord blood and perinatal stem cells.